Harvard Bioscience, Inc. to Continue Using Its Name
HOLLISTON, Mass., April 10 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today reported that the United States District Court, District of Massachusetts has denied Harvard University's request for a preliminary injunction prohibiting Harvard Bioscience, Inc. from using the name "Harvard." The Court did issue an order that directs Harvard Bioscience not to use the "Harvard" name in the color crimson, or in a font similar to the font used by the University.
"The Harvard Apparatus and Harvard Bioscience names have been in use for at least a hundred years and twenty years, respectively", commented Chane Graziano, CEO of Harvard Bioscience, "and are well known among researchers around the world. We do not expect that complying with this order by the Court will have any material impact on our business, financial condition or results of operations."
Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. HBIO sells approximately 10,000 products to thousands of researchers in over 60 countries though its 1,000 page catalog, and through its distributors, the most notable of which is AP Biotech. HBIO has sales and manufacturing operations in the United States, the United Kingdom, and Germany with sales facilities in France and Canada.
The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the Company's expectations as to the impact on its business, financial and results of operations resulting from complying with the Court's order, and the Company's plans, objectives and intentions contained in this press release that are not historical facts. The Company cautions that the denial of a preliminary injunction is not a final decision on the merits of the case and that the Court's denial of the preliminary injunction may not be indicative of the Company's actual likelihood of success on the merits. Other factors that may cause the Company's actual results to differ materially from those in the forward looking statements include those set forth under the heading "Important Factors That May Affect Future Operating Results" in the Companies filing on Form 10-K for the fiscal year ended December 31, 2000, as well as other risks described in the Company's public filings or factors, if any, of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information.
For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com. SOURCE Harvard Bioscience, Inc.
CONTACT: Jim Warren, CFO, jwarren@harvardbioscience.com, or David Green, or President, dgreen@harvardbioscience.com, or Chane Graziano, CEO, cgraziano@harvardbioscience.com/
Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.